Moderna: Q1 Earnings Insights Moderna (NASDAQ:MRNA) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Benzinga · May 4, 2022
Pfizer hopes to submit little-kid vaccine data by early June Pfizer now hopes to tell U.S. regulators how well its COVID-19 vaccine works in the littlest kids by early June The Independent UK · May 3, 2022
Pfizer accused of Covid profiteering as first-quarter sales hit $26bn Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill The Guardian - UK · May 3, 2022
Moderna Bullish On COVID-19 Vaccine For Younger Kids To Be Ready Next Month: Reuters Moderna Inc's (NASDAQ:MRNA) chief medical officer said that its COVID-19 vaccine for children under six years old would be ready for review by the FDA panel when it meets in June. "I think the FDA now has all of the core fundamental data they need to be able to begin an application review.… Benzinga · May 2, 2022
Here's What To Watch On Moderna As The Stock Flies Higher Moderna, Inc (NASDAQ: MRNA) was trading over 8% higher at one point on Monday morning, bouncing up within a descending channel pattern on the daily chart. Benzinga · May 2, 2022
American Express And 2 Other Stocks Insiders Are Selling Gold futures traded lower by around 2.5% on Monday. Investors, meanwhile, focused on some notable insider trades. Benzinga · May 2, 2022
Pressure builds for COVID vaccines approval for littlest kids Moderna's request for approval of its COVID -19 vaccine in children under six years amps up pressure on the Food and Drug Administration to act quickly to approve the shots. Axios · May 2, 2022
Chinese Omicron-specific mRNA COVID vaccine candidate to be trialed in UAE China's Suzhou Abogen Biosciences Co said its COVID-19 vaccine candidate using the messenger RNA (mRNA) technology and targeting the Omicron variant has obtained clinical trial approval in the United Arab Emirates. Reuters · Apr 30, 2022
FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For Kids, Plus Novavax EUA The FDA has set up June meeting dates to review COVID-19 vaccine submissions, noting that the dates are tentative as none of the submissions are complete. The agency reserved June 8, 21, and 22 for virtual meetings of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) to review Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE)… Benzinga · Apr 29, 2022
FDA sets June meetings on COVID vaccines for youngest kids The Food and Drug Administration has set tentative dates in June to publicly review COVID-19 vaccines for the youngest American children The Independent UK · Apr 29, 2022
Scottish campaigners protest at Pfizer office as 'vaccine equity' motion voted down CAMPAIGNERS from Global Justice Now Scotland have stated they are “outraged” as shareholders at pharmaceutical multinationals Pfizer and Moderna… The National (Scotland) · Apr 29, 2022
Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6 Years Moderna Inc (NASDAQ: MRNA) Benzinga · Apr 28, 2022
Moderna seeks FDA approval of Covid vaccine for children aged six months to five years old The request arrives one month after the drug company said its two-dose jabs provided immune protection in youngest children The Independent UK · Apr 28, 2022
Covid vaccine: Moderna seeks US approval for jab for kids under 6 Trials showed the jab was 37 per cent effective for two and five-year-olds and 51 per cent for children between six months and the age of two Evening Standard · Apr 28, 2022
Tribune News Service · Apr 28, 2022 Moderna applies for US clearance of COVID shot for young kids Moderna Inc. applied for emergency use authorization for its COVID-19 vaccine in children from six months to under 6 years old after a successful trial showed two doses generate high levels of antibodies to the virus.
Benzinga · Apr 28, 2022 The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates Here's a roundup of top developments in the biotech space over the last 24 hours:
The Independent UK · Apr 28, 2022 Moderna seeks to be 1st with COVID shots for littlest kids Moderna is asking U.S. regulators to open its COVID-19 vaccine to the nation's youngest children
Axios · Apr 28, 2022 Moderna seeks emergency authorization for COVID-19 vaccine in young children Moderna said last month its vaccine for kids generated a strong immune response.
Roll Call · Apr 28, 2022 Moderna asks FDA to authorize COVID-19 vaccine for kids under 6 - Roll Call Moderna said Thursday that it asked the FDA for emergency use authorization of its COVID-19 vaccine in kids under age 6.
Salon · Apr 26, 2022 Another delay for five-and-under vaccine The issue isn't around safety, but instead messaging and vaccine effectiveness
Roll Call · Apr 26, 2022 Most Americans have COVID-19 antibodies as case numbers rise - Roll Call The percentage of people with antibodies increased from 34 percent in December to roughly 58 percent in February, the CDC said.
Benzinga · Apr 26, 2022 Moderna Whale Trades For April 26 Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
The Conversation · Apr 26, 2022 How Robert Langer, a pioneer in delivering mRNA into the body, failed repeatedly but kept going: 'They said I should give up, but I don't like to give up' The mRNA vaccines developed against COVID-19 owe a lot to the work of Robert Langer, a pioneer in the delivery of mRNA. Langer, who is the Massachusetts Institute of Technology David H. Koch Institute Professor and director of the Langer Lab, helped lay the foundation for the underlying delivery mechanism…
The Independent UK · Apr 25, 2022 Pass urgent COVID funding or more will die, White House says After two years at the front of the line for COVID-19 vaccines and treatments, the U.S. could soon have to begin taking a number
Benzinga · Apr 25, 2022 Poland, Moderna Working Towards Increased Flexibility Of COVID-19 Vaccine Contracts: Reuters Poland can compromise with Moderna Inc (NASDAQ:MRNA) on increasing the flexibility of COVID-19 vaccine contracts, Reuters reported citing the health minister, striking an upbeat tone after initial talks with the company. Poland has said it will not take or pay for more doses of the COVID-19 vaccine under the European Union's supply contract. Reuters…